• Akari Therapeutics shareholders approved expanding the 2023 Plan share pool at the October 28, 2026 special general meeting.
• The authorization covers an increase of 144,000,000,000 ordinary shares, equivalent to 1,800,000 American Depositary Shares (ADSs).
• The authorized pool rises from 19,806,000,000 to 163,806,000,000 ordinary shares, equivalent to 2,047,575 ADSs.
• Up to 855,637,300 additional ordinary shares may become available if 2014 Plan awards are forfeited, canceled or expire unexercised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-049446), on October 30, 2026, and is solely responsible for the information contained therein.